secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001731122-24-001548
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Virpax receives Nasdaq deficiency notice; CEO and CFO resign citing policy disagreements
--------------------------------------------------------------------------------

- Nasdaq notified Virpax that its bid price was below $1.00 for 30 consecutive days; compliance deadline April 2, 2025.
- CEO Gerald Bruce and CFO Vinay Shah resigned Oct 5 effective immediately, citing disagreements with Board's execution of policies.
- Board appointed director Jatinder Dhaliwal as CEO effective Oct 6; Katharyn Field joins audit committee replacing Dhaliwal.
- Company may consider a reverse stock split to regain compliance, but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/0001731122-24-001548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/e6009_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-001548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer